Literature DB >> 25219375

Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.

R Castañeda-Arellano1, A I Feria-Velasco1, M C Rivera-Cervantes2.   

Abstract

Erythropoietin in the nervous system is a potential neuroprotective factor for cerebral ischemic damage due to specific-binding to the erythropoietin receptor, which is associated with survival mechanisms. However, the role of its receptor is unclear. Thus, this work assessed whether a low dose (500UI/Kg) of intranasal recombinant human erythropoietin administered 3h after ischemia induced changes in the activation of its receptor at the Tyr456-phosphorylated site in ischemic hippocampi in rats. The results showed that recombinant human erythropoietin after injury maintained cell survival and was associated with an increase in receptor phosphorylation at the Tyr456 site as an initial signaling step, which correlated with a neuroprotective effect.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EpoR phosphorylation; Erythropoietin; Intranasal delivery; Ischemia; Neuroprotection

Mesh:

Substances:

Year:  2014        PMID: 25219375     DOI: 10.1016/j.neulet.2014.09.013

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Neuroregenerative and protective functions of Leukemia Inhibitory Factor in perinatal hypoxic-ischemic brain injury.

Authors:  Jie Lin; Yusuke Niimi; Mariano Guardia Clausi; Hur Dolunay Kanal; Steven W Levison
Journal:  Exp Neurol       Date:  2020-04-19       Impact factor: 5.330

2.  rhEPO Enhances Cellular Anti-oxidant Capacity to Protect Long-Term Cultured Aging Primary Nerve Cells.

Authors:  Huqing Wang; Jiaxin Fan; Mengyi Chen; Qingling Yao; Zhen Gao; Guilian Zhang; Haiqin Wu; Xiaorui Yu
Journal:  J Mol Neurosci       Date:  2017-06-21       Impact factor: 3.444

Review 3.  Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.

Authors:  Dapinder Kaur; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Syed Shams Ul Hassan; Mohammad Mehedi Hasan; Saurabh Bhatia; Ahmed Al-Harassi; Haroon Khan; Simona Bungau
Journal:  Metab Brain Dis       Date:  2021-08-26       Impact factor: 3.584

Review 4.  Erythropoietin regulates signaling pathways associated with neuroprotective events.

Authors:  Cornelio-Martínez Sergio; Castañeda-Arellano Rolando
Journal:  Exp Brain Res       Date:  2022-03-02       Impact factor: 1.972

5.  Electroacupuncture at GV20 and ST36 Exerts Neuroprotective Effects via the EPO-Mediated JAK2/STAT3 Pathway in Cerebral Ischemic Rats.

Authors:  Hong Xu; Ya-Min Zhang; Hua Sun; Su-Hui Chen; Ying-Kui Si
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-07       Impact factor: 2.629

6.  Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo.

Authors:  Meng Wang; Wenhui Yan; Yuan Liu; Hao Hu; Qiang Sun; Xinlin Chen; Weijin Zang; Lina Chen
Journal:  Sci Rep       Date:  2017-06-05       Impact factor: 4.379

Review 7.  Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.

Authors:  Carolina Castillo Hernández; Carlos Felipe Burgos; Angela Hidalgo Gajardo; Tiare Silva-Grecchi; Javiera Gavilan; Jorge Roberto Toledo; Jorge Fuentealba
Journal:  Neural Regen Res       Date:  2017-09       Impact factor: 5.135

Review 8.  The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.

Authors:  Yuanyuan Ma; Zhiyuan Zhou; Guo-Yuan Yang; Jing Ding; Xin Wang
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

9.  Erythropoietin signaling increases neurogenesis and oligodendrogenesis of endogenous neural stem cells following spinal cord injury both in vivo and in vitro.

Authors:  Hui Zhang; Xiao Fang; Dake Huang; Qingli Luo; Meijuan Zheng; Kangkang Wang; Le Cao; Zongsheng Yin
Journal:  Mol Med Rep       Date:  2017-10-25       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.